Williams Keith L, Broadbridge Carissa L
Department of Psychology, Oakland University, 224 Pryale Hall, Rochester, MI 48309, USA.
Alcohol. 2009 Mar;43(2):119-26. doi: 10.1016/j.alcohol.2008.11.003.
The opioid antagonist naltrexone (NTX) is used to treat alcohol dependence and may reduce alcohol consumption by selectively blocking opioid receptors. In rat experiments, discrepancy exists across studies regarding the potency of NTX to reduce ethanol consumption. One cause of this discrepancy may be the use of different routes of NTX administration (e.g., intraperitoneal vs. subcutaneous). The purpose of this study was to directly compare the effects of intraperitoneal and subcutaneous injections of NTX on ethanol self-administration. Rats pressed a lever for a sweetened ethanol solution (10% wt/vol in 0.1% saccharin) during 20 min daily sessions. One group received intraperitoneal injections of 1, 3, 10, and 30 mg/kg NTX before the sessions. Another group received subcutaneous injections of 0.03, 0.1, 0.3, and 1 mg/kg NTX before the sessions. The group that received subcutaneous NTX was also tested with a single intraperitoneal injection of 0.3 mg/kg NTX. Naltrexone significantly reduced ethanol self-administration, and NTX was more potent when administered via subcutaneous injection versus intraperitoneal injection. Ethanol intake (g/kg) was significantly reduced after subcutaneous injection of NTX 0.1 mg/kg and higher. In contrast, ethanol intake was significantly reduced after intraperitoneal injection of NTX 3 mg/kg and higher. A comparison of the NTX ED(50) values showed that subcutaneous NTX was approximately 30-fold more potent than intraperitoneal NTX. For the subcutaneous 0.3 mg/kg NTX dose, a detailed bin analysis showed that responding during the first 2 min after injection was similar to that during the first 2 min after a saline injection while responding after NTX decreased in subsequent bins. These findings suggest that researchers should carefully consider the route of NTX administration when discussing potency and selectivity of NTX's effects on ethanol-related behaviors in rats. These findings further support the notion that NTX acts by terminating responding early rather than reducing the initial responding.
阿片类拮抗剂纳曲酮(NTX)用于治疗酒精依赖,它可能通过选择性阻断阿片受体来减少酒精摄入量。在大鼠实验中,关于NTX降低乙醇摄入量的效力,各项研究结果存在差异。造成这种差异的一个原因可能是NTX的给药途径不同(例如,腹腔注射与皮下注射)。本研究的目的是直接比较腹腔注射和皮下注射NTX对乙醇自我给药的影响。大鼠每天在20分钟的实验时段内按压杠杆以获取含糖乙醇溶液(0.1%糖精中的10%重量/体积)。一组在实验时段前接受1、3、10和30mg/kg NTX的腹腔注射。另一组在实验时段前接受0.03、0.1、0.3和1mg/kg NTX的皮下注射。接受皮下NTX的组也用0.3mg/kg NTX的单次腹腔注射进行了测试。纳曲酮显著降低了乙醇自我给药量,并且与腹腔注射相比,皮下注射NTX时效力更强。皮下注射0.1mg/kg及更高剂量的NTX后,乙醇摄入量(g/kg)显著降低。相比之下,腹腔注射3mg/kg及更高剂量的NTX后,乙醇摄入量显著降低。NTX的半数有效剂量(ED50)值比较表明,皮下NTX的效力比腹腔NTX高约30倍。对于皮下0.3mg/kg NTX剂量,详细的时段分析表明,注射后前2分钟的反应与注射生理盐水后前2分钟的反应相似,而NTX注射后后续时段的反应则减少。这些发现表明,研究人员在讨论NTX对大鼠乙醇相关行为的效力和选择性时,应仔细考虑NTX的给药途径。这些发现进一步支持了NTX通过提前终止反应而非减少初始反应来发挥作用的观点。